Highland Therapeutics to Present at Piper Jaffray Healthcare Conference
TORONTO, Nov. 27, 2013 /PRNewswire/ - Highland Therapeutics Inc. ("Highland"), an emerging pharmaceutical company, today announced that the Company's President and Chief Executive Officer, David Lickrish, will present at the 25th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York City. Highland's presentation is scheduled for Wednesday, December 4, 2013 at 2:10pm EST.
A live webcast of the presentation can be accessed by visiting www.highlandtherapeutics.com. The webcast will be archived on the Company's website for 30 days.
Mr. Lickrish will provide the investment community with an update on the clinical development of HLD-200, Highland's novel formulation of methylphenidate for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). HLD-200 is designed to be taken at bedtime, to provide clinically meaningful control of symptoms of ADHD upon wakening and throughout the day.
Highland intends to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) prior to year-end. Based on feedback from the FDA, Highland plans to initiate a pivotal trial with HLD-200 in 2014.
Methylphenidate is currently sold under the brand name Concerta by Janssen Pharmaceuticals, Inc. (a Johnson & Johnson company) and Ritalin/Ritalin LA by Novartis Pharmaceuticals Corporation.
About Highland Therapeutics Inc.
Highland Therapeutics Inc. is an emerging pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technologies to optimize the delivery of previously approved drug products. The Company's lead products, HLD-100 and HLD-200, are novel formulations of the psychostimulants (amphetamine and methylphenidate, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease - the lack of symptom control during the early morning routine. The clinically meaningful benefits of Highland's approach are targeted at helping ADHD patients and their families improve the quality of their lives.
Highland Therapeutics Inc. is a client of MaRS Discovery District's Life Sciences and Healthcare practice, which provides advisory services and support to help Ontario life sciences companies grow and commercialize their businesses.
This press release contains forward-looking information, which reflects Highland's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Highland's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Highland assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Highland Therapeutics Inc.